Pericardial effusion with tamponade physiology induced by nivolumab

Int J Cardiol. 2016 Nov 1:222:613-614. doi: 10.1016/j.ijcard.2016.08.023. Epub 2016 Aug 3.

Authors

Jennifer Nesfeder¹, Ashley N Elsensohn², Munveer Thind¹, James Lennon³, Steven Domsky⁴

Affiliations

¹ Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, United States.
² Department of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, United States. Electronic address: elsensohna@mlhs.org.
³ Division on Hematology and Oncology, Lankenau Medical Center, Wynnewood, PA, United States.
⁴ Division of Cardiovascular Disease, Lankenau Medical Center, Wynnewood, PA, United States.

PMID: 27517649
DOI: 10.1016/j.ijcard.2016.08.023

No abstract available

Keywords: Immune-related adverse events; Nivolumab; Pericardial effusion.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antineoplastic Agents / adverse effects*
Cardiac Tamponade / chemically induced*
Cardiac Tamponade / diagnosis*
Cardiac Tamponade / physiopathology
Humans
Male
Middle Aged
Nivolumab
Pericardial Effusion / chemically induced*
Pericardial Effusion / diagnosis*
Pericardial Effusion / physiopathology

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Nivolumab